Challenges of BCLC stage C hepatocellular carcinoma Results of a single-institutional experience on stereotactic body radiation therapy

doi:10.1097/MD.0000000000021561

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 醫務管理系(所) > 期刊論文 > Item 310902800/34098

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34098

標題:	Challenges of BCLC stage C hepatocellular carcinoma Results of a single-institutional experience on stereotactic body radiation therapy
作者:	Que, Jenny Lin, Chia-Hui Lin, Li-Ching Ho, Chung-Han
貢獻者:	Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Med Res
關鍵字:	Barcelona clinic liver cancer stage C hepatocellular carcinoma stereotactic body radiation therapy
日期:	2020
上傳時間:	2022-11-18 11:23:50 (UTC+8)
出版者:	Lippincott Williams & Wilkins
摘要:	In this study, we evaluated the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). This retrospective study evaluated 139 patients with BCLC stage C HCC who underwent CyberKnife SBRT between January 2009 and September 2017. All patients had BCLC-C, Child-Turcotte-Pugh score A-B. In-field control, overall survival (OS), progression free survival (PFS), and prognostic factors were evaluated. An objective response rate was achieved in 81.5% patients (complete response, 36.2%, partial response, 45.3%). The median survival was 15.44 months, and the 1-, 3-, 5-year OS rates were 56%, 28%, and 20%, respectively. The median PFS was 6 months, the PFS rate at 1-, 3-, and 5-year were 35%, 14%, and 10%, respectively. In-field control of 1 to 2 years was achieved in 85.1% of patients. The major pattern of failure was out-field intrahepatic failure which comprised 42.9% of patients. Multivariate analysis revealed that the Child-Turcotte-Pugh score, macrovascular invasion, advance stage (III-IV), and tumor response rate were independent predictors of OS. The result of our study shows that SBRT is a safe and effective therapeutic option for BCLC stage C HCC lesions that are unsuitable for standard loco-regional therapies, Moreover, SBRT has acceptable local control rates and low-treatment toxicity.
關聯:	Medicine, v.99, n.32, pp.9
显示于类别:	[醫務管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	646	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....